Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after ≥2 lines of prior systemic therapy and, more recently, for those who are refractory to or have relapsed within 12 mo of first-line chemoimmunotherapy [1]. In the pivotal Phase 1/2 ZUMA-1 trial, patients who received axi-cel had an objective response rate (ORR) of 83% (complete response [CR] rate, 58%) with a median follow-up of 27.1 mo [2].
